Fate Therapeutics financials
$2.380.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.1M | $1.3M | $1.4M | $1.7M | $1.9M | $1.6M | $1.9M | $3.1M | $6.8M | $1.9M | $1.7M | $1.9M |
| Gross profit | $2.1M | $1.3M | $1.4M | $1.7M | $1.9M | $1.6M | $1.9M | $3.1M | $6.8M | $1.9M | $1.7M | $1.9M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$31.1M | -$33.0M | -$34.7M | -$34.7M | -$37.0M | -$41.3M | -$61.7M | -$52.4M | -$45.1M | -$51.1M | -$48.1M | -$51.3M |
| Net income | -$30.2M | -$31.2M | -$32.4M | -$32.3M | -$34.1M | -$37.6M | -$52.2M | -$47.7M | -$38.4M | -$48.0M | -$44.1M | -$45.2M |
| Net margin | −1448.6% | −2402.8% | −2364.8% | −1852.4% | −1786.6% | −2309.5% | −2803.9% | −1551.0% | −567.4% | −2493.7% | −2632.6% | −2323.6% |
| Diluted EPS | $-0.25 | $-0.26 | $-0.27 | $-0.27 | $-0.29 | $-0.32 | $-0.44 | $-0.40 | $-0.33 | $-0.47 | $-0.45 | $-0.46 |
| EBITDA | -$28.4M | -$30.1M | -$31.7M | -$31.5M | -$33.7M | -$37.9M | -$42.2M | -$47.8M | -$40.4M | -$46.2M | -$43.2M | -$46.5M |
| Operating cash flow | -$23.4M | -$30.8M | -$23.3M | -$24.4M | -$24.6M | -$33.8M | -$27.8M | -$29.4M | -$32.3M | -$33.4M | -$36.6M | -$38.3M |
| Free cash flow | -$23.5M | -$31.1M | -$24.5M | -$26.6M | -$25.9M | -$35.0M | -$27.9M | -$29.9M | -$32.4M | -$33.4M | -$36.8M | -$38.8M |
| Diluted shares | 120.4M | 120.0M | 119.3M | 119.0M | 118.5M | 118.4M | 118.4M | 117.8M | 117.5M | 101.1M | 98.6M | 98.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $32.4M | $39.6M | $46.6M | $40.6M | $41.2M | $44.9M |
| Short-term investments | $121.3M | $135.3M | $157.0M | $174.8M | $181.6M | $195.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $260.1M | $284.9M | $318.9M | $343.7M | $371.6M | $398.7M |
| Total liabilities | $105.7M | $104.8M | $111.5M | $109.2M | $109.9M | $110.0M |
| Shareholders' equity | $153.4M | $179.7M | $207.2M | $234.1M | $261.4M | $288.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology